CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
This article was originally published in The Pink Sheet Daily
Executive Summary
Data suggesting some link between CYP2C9 or VKORC1 gene mutations and a patient's likelihood of fatal excessive bleeding in response to the drug are enough for a coverage-with-evidence-development policy, where beneficiaries enrolled in qualifying trials are covered.
You may also be interested in...
Genetic Testing, But No Drugs, On Revised List Of Potential Medicare NCD Topics
CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.
Raising The Bar For Anticoagulants? Warfarin Genotype Results Announced
Results of a prospective observational study conducted by the pharmacy benefit manager Medco and the Mayo Clinic link more precise warfarin dosing through genotyping to a 30 percent reduction in hospitalization rates from any cause within six months of starting the drug
Raising The Bar For Anticoagulants? Warfarin Genotype Results Announced
Results of a prospective observational study conducted by the pharmacy benefit manager Medco and the Mayo Clinic link more precise warfarin dosing through genotyping to a 30 percent reduction in hospitalization rates from any cause within six months of starting the drug